HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced results from a large randomized controlled trial showing that its 308nm Excimer laser, when combined with an oral Janus kinase (JAK) inhibitor, delivers superior outcomes for adults with localized non-segmental vitiligo.
The 251-patient study, published in the International Journal of Dermatology, demonstrated that the combination therapy achieved unprecedented response rates, faster results, and durable repigmentation compared to monotherapy or conventional treatment.
Key findings included a 14.2% increase in repigmentation with the combination approach, a 100% significant efficacy rate after 52 weeks, and stable pigmentation in 96.5% of patients one year after treatment, with relapse occurring in just 8.8% of cases. Importantly, no serious or persistent adverse events were reported.
“This investigator-initiated study, which features a much larger patient population than typically seen in contemporary dermatology trials, highlights the continued interest in our Excimer laser technology and the promise of combination therapy,” said Dr. Dolev Rafaeli, CEO of STRATA. “Dermatologists continue to rely on the superior performance of our Excimer technology for durable repigmentation in difficult-to-manage skin conditions. The addition of JAK inhibitors enhances efficacy without compromising safety, and patients are experiencing high stability with minimal relapse. These results strongly validate our efforts to expand reimbursement access for vitiligo, psoriasis, and other conditions.”
The excimer laser has long been recognized as a cornerstone therapy for difficult-to-treat inflammatory and autoimmune skin diseases. With over 400 peer-reviewed papers supporting its safety and effectiveness, the latest study provides one of the most robust evidence bases yet, reinforcing its role in modern dermatology and strengthening STRATA’s case for broader coverage by 2026.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.